NCT01359449已完成3 期
Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.
研究概览
简要总结
The purpose for this study is to demonstrate the safety and immunogenicity of two doses of Menactra® administered between 12 and 18 months of age and concomitantly with routine immunization with two different provincial schedule
Primary Objectives:
- To describe the immunogenicity of Menactra® administered concomitantly with routine immunizations at 12 and 18 months in naïve or Menjugate-primed (MenC-primed) infants (measured by serum bactericidal assay using baby rabbit complement [SBA-BR])
- To describe the immunogenicity of MenC administered concomitantly with routine immunizations at 12 months of age (measured by SBA-BR)
Secondary Objectives:
Safety
- To describe the safety profile of Menactra® and MenC vaccines after each dose when given concomitantly with routine immunization.
Immunogenicity
- To describe the immunogenicity of both vaccines using serum bactericidal assay using human complement [SBA-HC]
- To describe the immunogenicity of Pediacel administered at 18 months.
详细描述
Participants depending on their groups will receive either two doses of Menactra vaccine concomitantly with the routinely recommended vaccines or one dose of MenC vaccine concomitantly with the routinely recommended vaccines and will be monitored for safety and immunogenicity. The duration of each subject's participation in the trial will be approximately 7 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 12 Months 至 18 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 12 months (365 to 400 days) on the day of inclusion
- •Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg
- •Informed consent form has been signed and dated by the parent(s) or other legally authorized representative
- •Subject and parent/legal representative are able to attend all scheduled visits and to comply with all trial procedures
- •Group 1: Subject has received 3 primary vaccination doses of Pediacel as per routine immunization schedule
- •Group 3: Subject has received two doses of MenC vaccine at approximately 2 and 4 months of age as per Alberta immunization schedule.
排除标准
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination(s), which may be received at least two weeks before study vaccines
- •Planned receipt of any vaccine in the 4 weeks following any trial vaccination
- •Previous vaccination against Meningococcal disease OR
- •Subject has previously received only one dose of MenC vaccine, or more than two doses of MenC vaccine, or two doses of MenC vaccine with the most recent dose received in the past 6 months
- •Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •Personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as reported by the parent/legal representative
- •History of documented invasive meningococcal disease
- •At high risk for meningococcal disease during the trial
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
- •History of contraindication to receipt of pertussis-containing vaccine
- •Thrombocytopenia, as reported by the parent/legal representative, contraindicating intramuscular vaccination
- •Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- •History of seizures
- •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- •History of Guillain-Barré Syndrome.
结局指标
主要结局
Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.
时间窗: 28 days post-vaccination
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
Number of Participants With Serum Bovine Albumin Baby Rabbit Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.
时间窗: 28 days post-vaccination
Immunogenicity tests were performed at 19 months of age in Menactra Vaccine Group after Menactra® vaccination and performed at 13 months and 19 months of age in the Menjugate Vaccine Group after Menjugate® vaccination
次要结局
- Geometric Mean Titers of Serum Bovine Albumin Human Complement Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.(28 days post-vaccination)
- Number of Participants With Serum Bovine Albumin Human Complement Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.(28 days post-vaccination)
- Geometric Mean Titers of Antibodies to Pediacel® Vaccine Antigens in Participants That Received a Dose of Menactra® at 12 and 18 Months of Age, Respectively, and a Booster Dose of Pediacel® Vaccine at 18 Months of Age.(28 days post-vaccination)
- Summary of Participants With Booster Response for Pediacel® Vaccine Antigens After Vaccination With Pediacel® Vaccine (Menactra Vaccine Group)(28 days post-vaccination)
- Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate Vaccine at 12 Months of Age(Day 0 up to Day 7 post-vaccination)
- Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With a Second Dose of Menactra Vaccine at 18 Months of Age(Day 0 up to Day 7 post-vaccination)
- Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Any of the Study Vaccination(Day 0 up to Day 7 post-vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeMeningococcal InfectionHaemophilus Influenzae Serotype b (Hib)TetanusDiphtheriaMeningitisPertussisNCT01659996Sanofi Pasteur, a Sanofi Company1,394
已完成
3 期
A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in IndiaMeningococcal InfectionMeningitisNCT01086969Sanofi300
已完成
3 期
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South KoreaMeningococcal DiseaseMeningitisNCT01642589Sanofi Pasteur, a Sanofi Company300
已完成
3 期
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersMeaslesVaricellaMumpsMeningococcal MeningitisRubellaNCT00483574Sanofi Pasteur, a Sanofi Company1,378
已完成
2 期
Dose Comparison Study of Menactra® in US ChildrenMeningococcal InfectionNeisseria MeningitidisMeningitisNCT00700635Sanofi Pasteur, a Sanofi Company333